- 201-500 Employees
- Based in New York City, New York
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia.
REPORT RATINGS4.7 / 5.0 (121)
Intercept Pharma reports have an aggregate usefulness score of 4.7 based on 121 reviews.
Most Recent Annual Report
2022 Annual Report and Form 10K
Intercept Pharma does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Please fill out the form below and click "Place Order" to complete your order.
Older/Archived Annual Reports